Plain-English translation of NCT06561854 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a steroid medication, can be safely stopped after just 2 cycles (about 8 weeks) of treatment for relapsed multiple myeloma—instead of continuing it for as long as the cancer responds. All patients receive the same strong chemotherapy combinations; the study compares whether stopping the steroid early works just as well as keeping it going.
Steroids like can cause side effects—bone loss, infection risk, sleep problems, and mood changes—especially over long periods. Doctors want to know if patients can get the same benefit from the medication for a shorter time, reducing these unwanted effects while keeping the cancer under control.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: one receiving the steroid with every cycle of chemotherapy, and the other stopping the steroid after 2 cycles while continuing the other chemotherapy drugs. You would receive treatment on a set schedule at a participating hospital, with regular visits for medication infusions and blood tests to monitor your cancer and how well you're tolerating the treatment. Your doctor will track how your myeloma responds and watch for any side effects throughout the study.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France